Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

Trastuzumab deruxtecan improved PFS vs chemotherapy in pretreated, HR-positive, HER2-low or -ultralow metastatic breast cancer.

Related Keywords

Connecticut ,United States ,New Haven ,Daiichi Sankyo ,Daichii Sankyo ,Roche Genentech ,Ian Krop ,Bristol Myers Squibb ,Glaxosmithkline ,European Society Of Breast Cancer Specialists ,Pfizer ,Guardant Health ,Samsung ,Clinical Trials Office ,Novartis ,Clinical Sciences At Yale Cancer Center ,Boehringer Ingelheim ,Gilead Sciences ,Astrazeneca ,Foundation Medicine ,Clinical Sciences ,Yale Cancer Center ,European Society ,Breast Cancer Specialists ,Ellipses Pharma ,Blueprint Medicines ,Exact Sciences ,Hengrui Therapeutics ,